Can divergent plasmin-antiplasmin-carbon monoxide interactions in young, healthy tobacco smokers explain the 'smoker's paradox'?

Blood Coagulation and Fibrinolysis

Volumn 24, Issue 4, 2013, Pages 381-385

  Nielsen, Vance G ^a   Hafner, David T ^a   Steinbrenner, Evangelina B ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

carbon monoxide; fibrinolysis; smoking; thrombelastography

Indexed keywords

ANTIPLASMIN; CARBON MONOXIDE; CARBOXYHEMOGLOBIN; PLASMIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; FIBRINOLYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; MOLECULAR INTERACTION; PRIORITY JOURNAL; SMOKING; THROMBOELASTOGRAPHY; THROMBUS;

ADOLESCENT; ADULT; ANTIFIBRINOLYTIC AGENTS; CARBON MONOXIDE; CARBOXYHEMOGLOBIN; CASE-CONTROL STUDIES; FEMALE; FIBRINOLYSIN; HUMANS; MALE; MIDDLE AGED; PLASMA; SMOKING; THROMBELASTOGRAPHY; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84877701741     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32835d53ec     Document Type: Article

References (35)

1. Agarwal S. The association of active and passive smoking with peripheral arterial disease: results from NHANES 1999-2004. Angiology 2009;60:335-345.
2. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-189. (Pubitemid 43076437)
3. Shah RS, Cole JW. Smoking and stroke: the more you smoke the more you stroke. Expert Rev Cardiovasc Ther 2010;8:917-932.
4. Oliveria A, Barros H, Maciel HJ, Lopes C. Tobacco smoking and acute myocardial infarction in young adults: a population-based case-control study. Prevent Med 2007;44:311-316. (Pubitemid 46550680)
5. Zahger D, Cercek B, Cannon CP, Jorday M, Davis V, Braunwald E, Shah PK. How do smokers differ from nonsmokers in their response to thrombolysis(The TIMI-4 Trial). Am J Cardiol 1995;75:232-236.
6. Angeja BG, Kermgard S, Chen MS, McKay M, Murphy SA, Antman EM, et al. The smoker's paradox: insights from the angiographic substudies of the TIMI trials. J Thromb Thrombolysis 2002;13:133-139. (Pubitemid 35282630)
7. Katayama T, Iwasaki Y, Sakoda N, Yosioka M. The etiology of 'Smoker's paradox' in acute myocardial infarction with special emphasis on the association with inflammation. Int Heart J 2008;49:13-24. (Pubitemid 351663721)
8. Kievit PC, Brouwer MA, Veen G, Aengevaeren RM, Verheugt FWA. The smoker's paradox after successful fibrinolysis: reduced risk of reocclusion but no improved long-term cardiac outcome. J Thromb Thrombolysis 2009;27:385-393.
9. Wakabayashi K, Romaguera R, Laynez-Carnicero A, Maluenda G, Ben-Dor I, Sardi G, et al. Impact of smoking on acute phase outcomes of myocardial infarction. Coron Artery Dis 2011;22:217-222.
10. Chen KY, Rha SW, Li YJ, Jin Z, Minami Y, Park JY, et al. Smoker's paradox' in young patients with acute myocardial infarction. Clin Exp Pharmacol Physiol 2012;39:630-635.
11. Allen RA, Kluft C, Brommer EJ. Effect of chronic smoking on fibrinolysis. Arterioscler Thromb Vasc Biol 1985;5:443-450. (Pubitemid 15231299)
12. Hashimoto Y, Kobayashi A, Yamazaki N, Takada Y, Takada A. Relationship between smoking and fibrinolytic system with special reference to t-PA and PA inhibitor. Thromb Res 1988;51:303-311.
13. Haire WD, Goldsmith JC, Rasmussen J. Abnormal fibrinolysis in healthy male cigarette smokers: role of plasminogen activator inhibitors. Am J Hematol 1989;31:36-40. (Pubitemid 19127429)
14. Simpson AJ, Gray RS, Moore NR, Booth NA. The effects of chronic smoking on the fibrinolytic potential of plasma and platelets. Br J Haematol 1997;97:208-213. (Pubitemid 27179589)
15. Newby DE, Wright RA, Labinjoh C, Ludlam CA, Fox KAA, Boon NA, Webb DJ. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation 1999;99:1411-1415. (Pubitemid 29140904)
16. Wannamethee SG, Lowe GDO, Shaper AG, Rumley A, Lennon L, Whincup PH. Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart J 2005;26:1765-1773. (Pubitemid 41219850)
17. Barua RS, Sy F, Srikanth S, Huang G, Javed U, Buhari C, et al. Acute cigarette smoke exposure reduces clot lysis: association between altered fibrin architecture and the response to t-PA. Thromb Res 2010;126:426-430.
18. Meltzer ME, Doggen CJM, de Groot PG, Rosendaal FR, Lisman T. Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men. Blood 2010;116:529-536.
19. Sherif MA, Nienaber CA, Toelg R, Abdel-Wahab M, Geist V, Schneider S, et al. Impact of smoking on the outcome of patients treated with drugeluting stents: 1-year results from the prospective multicentre German drugeluting stent registry (DES.DE). Clin Res Cardiol 2011;100:413-423.
20. Abdel-Wahab M, Toelg R, Kassner G, Klatt L, Sherif MA, Geist V, Richardt G. Long-term clinical outcome of thin-strut cobalt-chromium stents in the drug-eluting stent era: results of the COBALT (comparison of bare-metal stents in all-comers' lesion treatment) registry. J Interven Cardiol 2011;24:496-504.
21. Cuneo A, Bramlage P, Hochadel M, Senges J, Nienaber C, Kuck KH, Tebbe U. Concurrent drug eluting/bare metal stent implantation during percutaneous coronary intervention in target vessel: outcomes and 1-year follow-up. Clin Res Cardiol 2012;101:281-288.
22. Meliga E, De Benedictis M, Gagnor A, Belli R, Scrocca I, Lombardi P, et al. Long-term outcomes of percutaneous coronary interventions with stent implantation in patients-40 years old. Am J Cardiol 2012;109:1717-1721.
23. Kimura T, Morimoto T, Nakagawa Y, Kawai K, Miyazaki S, Muramatsu T, et al. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation. Five-year outcome of the j-cypher registry. Circulation 2012;125:584-591.
24. Nielsen VG, Malayaman SN, Khan ES, Kirklin JK, George JF. Carbon monoxide releasing molecule-2 increases fibrinogen-dependent coagulation kinetics but does not enhance prothrombin activity. Blood Coagul Fibrinolysis 2010;21:349-353.
25. Nielsen VG, Cohen JB, Malayaman SN, Nowak M, Vosseller K. Fibrinogen is a heme-associated, carbon monoxide sensing molecule: a preliminary report. Blood Coagul Fibrinolysis 2011;22:443-447.
26. Nielsen VG, Arkebauer MR, Vosseller K. Redox-based thrombelastographic method to detect carboxyhemefibrinogen mediated hypercoagulability. Blood Coagul Fibrinolysis 2011;22:657-661.
27. Malayaman SN, Nielsen VG, Cohen JB, Machovec KA, Bernhardt BE, Arkebauer MR. Carbon monoxide releasing molecule-2 enhances alpha-2-antiplasmin activity. Blood Coagul Fibrinolysis 2011;22:345-348.
28. Arkebauer MR, Kanaparthy SS, Malayaman SN, Vosseller K, Nielsen VG. Carbon monoxide and nitric oxide modulate alpha-2-antiplasmin and plasmin activity: role of heme. Blood Coagul Fibrinolysis 2011;22:712-719.
29. Nielsen VG, Hafner DT, Steinbrenner EB. Tobacco smoke-induced hypercoagulation in human plasma: role of carbon monoxide. Blood Coagul Fibrinolysis 2013;24:405-410.
30. Nielsen VG, Kirklin JK, George JF, Messinger JD. Carbon monoxide releasing molecule-2 decreases thick diameter fibrin fibre formation in normal and factor XIII deficient plasma. Blood Coagul Fibrinolysis 2010;21:101-105.
31. Benowitz NL, Jacob 3rd P, Herrera B. Nicotine intake and dose response when smoking reduced-nicotine content cigarettes. Clin Pharmacol Ther 2006;80:703-714. (Pubitemid 44920221)
32. Cronenberger C, Mould DR, Roething H, Sarkar M. Population pharmacokinetic analysis of carboxyhaemoglobin concentrations in adult cigarette smokers. Br J Clin Pharmacol 2007;65:30-39. (Pubitemid 350265167)
33. Lupu F, Heim DA, Bachmann F, Hurni M, Kakkar VV, Kruithof EKO. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995;15:1444-1455.
34. Steins MB, Padro T, Li CX, Mesters RM, Ostermann H, Hammel D, et al. Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteries. Atherosclerosis 1999;145:173-180. (Pubitemid 29292713)
35. Nielsen VG, Arkebauer MR, Wasko KA, Malayaman SN, Vosseller K. Carbon monoxide releasing molecule-2 decreases fibrinolysis in vitro and in vivo in the rabbit. Blood Coagul Fibrinolysis 2012;23:104-107.